ESR1 and neoplasm: In order to identify novel biomarkers of tumor protection, we integrated the tamoxifen regulated gene signatures with gene expression signatures obtained from 255 ER+PR+ breast cancer patients who had received tamoxifen monotherapy for 5 years and were followed for response using distant metastasis free survival (DMFS) as an endpoint [40].